MRSN250117C1500
- 0.25
- 0.000.00%
Mersana Therapeutics Newsroom
BTIG Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $6
Mersana Therapeutics Transferred With Buy Rating at Citi
Citi Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Cuts Target Price to $5
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
A Quick Look at Today's Ratings for Mersana Therapeutics(MRSN.US), With a Forecast Between $6 to $8
TD Cowen Remains a Buy on Mersana Therapeutics (MRSN)
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
Buy Rating on Mersana Therapeutics: Anticipated Upside From XMT-1660 Development and Market Valuation Disconnect
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Announces Target Price $9
Mersana Therapeutics Is Maintained at Buy by Citigroup
Citi Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $5
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Chimerix (CMRX) and Mersana Therapeutics (MRSN)
Mersana Therapeutics Analyst Ratings
BTIG Initiates Mersana Therapeutics(MRSN.US) With Buy Rating, Announces Target Price $6
Truist Financial Issues a Buy Rating on Mersana Therapeutics (MRSN)
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating